Additionally, they observed that the combined treatment of cordycepin and anti-TIGIT could enhance the activation of NK cells and the activity of CD8+ TILs, reduce the expression of exhaustion marker genes in NK cells and CD8+ TILs, further supporting the anti-tumour potential of cordycepin in combination with TIGIT blockade (Chen et al., 2024). This evidence concerns the gene CD8A and neoplasm.